Professor of Clinical pharmacy
Henk-Jan Guchelaar is professor of Clinical Pharmacy
Henk-Jan (Hendrik Jan) Guchelaar studied pharmacy at the School of Pharmacy, State University Groningen, The Netherlands and finished his doctoral exam Pharmacy (cum laude) in 1988 and his Pharm D exam in 1989. He was trained in hospital pharmacy at the department of Pharmacy, University Medical Centre Groningen, The Netherlands and was licensed Hospital Pharmacist Specialist in 1992.
In 1993 he completed a PhD in Medicine and was licensed clinical pharmacologist by the Dutch Society of Clinical Pharmacology and Biopharmacy. From 1992-1996 he worked as a hospital pharmacist – head drug manufacturing department at the department of pharmacy, Hospital Medisch Spectrum Twente in Enschede, from 1996-1998 as hospital pharmacist - head clinical pharmaceutical and toxicological laboratory at the department of pharmacy, University Medical Centre (AMC) in Amsterdam, from 1998-2003 as Chair department of Pharmacy, University Medical Centre (AMC) in Amsterdam and since 2003 he was appointed Chair of the department Clinical Pharmacy & Toxicology, Leiden University Medical Centre (LUMC) in Leiden and Professor of Clinical Pharmacy, School of Medicine, University of Leiden, The Netherlands.
Since October 2009, he is also appointed professor of Clinical Pharmacy at the Leiden Academic Center of Drug Research, Faculty of Science, University of Leiden and Director of The Leiden Center for Translational Drug Discovery and Development (LCTD3). He has (co-)authored more than 125 articles in international peer reviewed scientific journals, more than 75 articles in Dutch journals and 17 (chapters in) books. He is program leader of the research program "Heterogeneity of drug efficacy and toxicity in relation to individual pharmacokinetics, pharmacodynamics and pharmacogenetics".
Heterogeneity of drug efficacy and toxicity in relation to individual pharmacokinetics, pharmacodynamics and pharmacogenetics. Principal investigators: Prof.Dr H.J. Guchelaar, Dr J.A.M. Wessels, Dr R.J.H.M. van der Straaten and Dr J. den Hartigh.
The ultimate goal of the programme is to optimize individual drug treatment by understanding and managing inter- and intraindividual variation of drug response both with respect to drug efficacy and toxicity. This patient care oriented programme of translational research is of great clinical importance at two different aspects. First, it is focused on developing, expanding and refining scientific methods (chemical analysis, therapeutic drug monitoring, pharmacogenetics) concerning pharmacotherapy. Secondly, it aims at contributing to improvement of pharmacotherapy. Monitoring drug concentrations and assessing drug (surrogate) effects, developing and applying clinical pharmacokinetic (PK)/pharmacodynamic (PD) models on the basis of population PK provides the means of understanding (and predicting) the variability of drug effects. More specifically, genetic variability (such as single nucleotide polymorphisms, gene expression) are taken into account and explain variable drug response.
The programme has a strong emphasis on drugs applied in oncology and immunology (rheumatoid arthritis, transplantation). It aims not only at a better understanding of mechanisms of variable drug efficacy and toxicity, but also at methods readily applicable in the treatment of patients with oncological and immunological disorders.
Professor of Clinical pharmacy
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research